Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
318 results
- CONTROLIndependent statistical analysis of Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00184548).
- Convalescent Plasma vs. Standard Plasma for COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Convalescent Plasma vs. Standard Plasma for COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04344535).
- Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- COPPSIndependent statistical analysis of COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04662060).
- CoVPN 3006A detailed statistical analysis of CoVPN 3006, a randomized phase 3 crossover study evaluating Moderna COVID-19 Vaccine against SARS-CoV-2 infection and COVID-19 disease through the Month 4 study visit.
- Cryoanalgesia vs. Epidural in the Nuss Procedure: Complete Statistical AnalysisIndependent statistical analysis of Cryoanalgesia vs. Epidural in the Nuss Procedure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02721017).
- dal-GenEComplete statistical analysis of the phase 3 dal-GenE trial evaluating dalcetrapib versus placebo in a genetically defined population with a recent acute coronary syndrome, including trial design, time-to-event endpoints, Cox modeling, multiplicity,…
- dal-GenEIndependent statistical analysis of Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Delirium Treatment With Acupuncture in Internal Medicine Departments: Complete Statistical AnalysisIndependent statistical analysis of Delirium Treatment With Acupuncture in Internal Medicine Departments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03398928).
- DELIVERIndependent statistical analysis of the DELIVER phase 3 trial of dapagliflozin in heart failure with preserved ejection fraction, including its dual primary time-to-event endpoints, Cox models, recurrent-event analysis, KCCQ analysis, safety, and…
- DELIVERIndependent statistical analysis of Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DEVOTEIndependent statistical analysis of DEVOTE (NCT01959529), the double-blind cardiovascular outcomes trial of insulin degludec versus insulin glargine in 7637 people with type 2 diabetes, covering the Cox non-inferiority analysis of MACE, negative…
- DIGESTIndependent statistical analysis of Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01285557).
- DOC-MEKIndependent statistical analysis of Docetaxel With or Without AZD6244 in Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01256359).
- Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01382706).
- Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency: primary endpoint results, effect estimate with confidence interval,…
- Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval,…
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Dose Finding Study of HP802-247 in Venous Leg Ulcers: Complete Statistical AnalysisIndependent statistical analysis of Dose Finding Study of HP802-247 in Venous Leg Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00852995).
- Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures: Complete Statistical AnalysisIndependent statistical analysis of Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- DREAMM-7Independent statistical analysis of the DREAMM-7 phase 3 China subpopulation trial evaluating belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
- DREAMM-8Independent statistical analysis of DREAMM-8, a randomized phase 3 trial of belantamab mafodotin plus pomalidomide and dexamethasone versus bortezomib plus pomalidomide and dexamethasone in multiple myeloma.
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: Complete Statistical AnalysisIndependent statistical analysis of DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: primary endpoint results, effect estimate…
- E5103Independent statistical analysis of E5103 (NCT00433511), a randomized phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in breast cancer.
- ECHELON-2Independent statistical analysis of ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas: primary endpoint results, effect estimate with confidence…
- Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients: Complete Statistical AnalysisIndependent statistical analysis of Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery: Complete Statistical AnalysisIndependent statistical analysis of Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes: primary endpoint results, effect estimate with confidence interval, sample-size…
- Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02): Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02): primary endpoint results, effect estimate…
- Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria: primary endpoint results, effect estimate with confidence…
- Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Electric Muscle Stimulation for Patients With Chronic Respiratory Failure: Complete Statistical AnalysisIndependent statistical analysis of Electric Muscle Stimulation for Patients With Chronic Respiratory Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01930643).
- ELEVATEIndependent statistical analysis of DC Migration Study for Newly-Diagnosed GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02366728).
- EMPACT-MIIndependent statistical analysis of EMPACT-MI, the randomized, placebo-controlled phase 3 trial of empagliflozin 10 mg after myocardial infarction: covariate-adjusted Cox hazard ratio for heart failure hospitalisation or death, negative binomial rate ratios…
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): Complete Statistical AnalysisIndependent statistical analysis of EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: Complete Statistical AnalysisIndependent statistical analysis of EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ESPRITComplete statistical analysis of ESPRIT, the randomized phase 3 trial of recombinant interleukin-2 in HIV-positive patients receiving antiretroviral therapy, including time-to-event, longitudinal CD4, categorical, safety, and statistical interpretation.
- Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…